{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:48:00Z","timestamp":1778730480922,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European League Against Rheumatism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1136\/ard-2022-223356","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T16:30:15Z","timestamp":1668097815000},"page":"3-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1406,"title":["EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-8877","authenticated-orcid":false,"given":"Josef S","family":"Smolen","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-6620","authenticated-orcid":false,"given":"Robert B M","family":"Landew\u00e9","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5248","authenticated-orcid":false,"given":"Sytske Anne","family":"Bergstra","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-8873","authenticated-orcid":false,"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-0229","authenticated-orcid":false,"given":"Alexandre","family":"Sepriano","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-0030","authenticated-orcid":false,"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[]},{"given":"Christopher John","family":"Edwards","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-3257","authenticated-orcid":false,"given":"Savia","family":"de Souza","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-7284","authenticated-orcid":false,"given":"Tanja A","family":"Stamm","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-3580","authenticated-orcid":false,"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8070-7062","authenticated-orcid":false,"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[]},{"given":"Joan M","family":"Bathon","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-5642","authenticated-orcid":false,"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[]},{"given":"Mario Humberto","family":"Cardiel","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2669-1247","authenticated-orcid":false,"given":"Katerina","family":"Chatzidionysiou","sequence":"additional","affiliation":[]},{"given":"Catalin","family":"Codreanu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-0932","authenticated-orcid":false,"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[]},{"given":"Alfons A","family":"den Broeder","sequence":"additional","affiliation":[]},{"given":"Khadija","family":"El Aoufy","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-4347","authenticated-orcid":false,"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-3671","authenticated-orcid":false,"given":"Jo\u00e3o Eurico","family":"Fonseca","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-946X","authenticated-orcid":false,"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[]},{"given":"Espen A","family":"Haavardsholm","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5592-724X","authenticated-orcid":false,"given":"Annamaria","family":"Iagnocco","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-9009","authenticated-orcid":false,"given":"Kim","family":"Lauper","sequence":"additional","affiliation":[]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[]},{"given":"Eduardo F","family":"Mysler","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[]},{"given":"Gyula","family":"Poor","sequence":"additional","affiliation":[]},{"given":"Gorica G","family":"Ristic","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6759-7521","authenticated-orcid":false,"given":"Felice","family":"Rivellese","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9016-2833","authenticated-orcid":false,"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[]},{"given":"Nikolay","family":"Stoilov","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-022X","authenticated-orcid":false,"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[]},{"given":"Annette","family":"van der Helm-van Mil","sequence":"additional","affiliation":[]},{"given":"Elsa","family":"van Duuren","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-3859","authenticated-orcid":false,"given":"Theodora P M","family":"Vliet Vlieland","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-3073","authenticated-orcid":false,"given":"Ren\u00e9","family":"Westhovens","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223356_bib1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib2","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"The 2010 American College of rheumatology \/ European League against rheumatism classification criteria for rheumatoid arthritis","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international Task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib6","author":"Food and Drug Administration USA"},{"key":"10.1136\/ard-2022-223356_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223356_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223356_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib10","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"Agree II: advancing Guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"10.1136\/ard-2022-223356_bib11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review Informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib12","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research Informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1136\/ard.2009.127332","article-title":"Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review Informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Gorter","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, persistence and safety of glucocorticoids: a systematic literature review Informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review Informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research Informing the 2022 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib17","author":"Howick"},{"key":"10.1136\/ard-2022-223356_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib19","series-title":"The world medicines situation 2011. rational use of medicines","author":"Holloway","year":"2011"},{"key":"10.1136\/ard-2022-223356_bib20","doi-asserted-by":"crossref","first-page":"e000256","DOI":"10.1136\/rmdopen-2016-000256","article-title":"From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?","volume":"4","author":"Molendijk","year":"2018","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223356_bib21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/annrheumdis-2021-220043","article-title":"Preclinical models of arthritis for studying immunotherapy and immune tolerance","volume":"80","author":"Meehan","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/annrheumdis-2020-219682","article-title":"Circulating blood metabolite trajectories and risk of rheumatoid arthritis among military personnel in the Department of defense Biorepository","volume":"80","author":"Costenbader","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib23","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","article-title":"2016 update of the EULAR recommendations for the management of early arthritis","volume":"76","author":"Combe","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib24","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1136\/annrheumdis-2012-201519","article-title":"Near misses of ACR\/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions","volume":"71","author":"Studenic","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"82","author":"Studenic","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/annrheumdis-2019-216529","article-title":"Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR\/EULAR Boolean criteria optimal?","volume":"79","author":"Studenic","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international Task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/art.27740","article-title":"Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223356_bib29","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/art.39714","article-title":"Brief report: estimating disease activity using Multi-Biomarker disease activity scores in rheumatoid arthritis patients treated with abatacept or adalimumab","volume":"68","author":"Fleischmann","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223356_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/art.39996","article-title":"Brief report: remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria","volume":"69","author":"Smolen","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223356_bib31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/acr.23866","article-title":"Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database","volume":"71","author":"Ferreira","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223356_bib32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/annrheumdis-2019-216819","article-title":"Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)","volume":"79","author":"Ramiro","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0140-6736(90)90771-V","article-title":"Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up","volume":"335","author":"van der Heijde","year":"1990","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223356_bib34","doi-asserted-by":"crossref","first-page":"211073001","DOI":"10.1177\/1759720X211073001","article-title":"Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge","volume":"14","author":"Dima","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223356_bib35","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/acr.23759","article-title":"Low persistence rates in patients with rheumatoid arthritis treated with triple therapy and adverse drug events associated with sulfasalazine","volume":"71","author":"Erhardt","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223356_bib36","article-title":"Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Ase as Bridging Therapy in Patients with Rheumatoid Arthritis [abstract]","volume":"74","author":"van Ouwerkerk","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223356_bib37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semarthrit.2010.03.003","article-title":"A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries","volume":"40","author":"Curtis","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223356_bib38","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-Term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib39","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib40","doi-asserted-by":"crossref","first-page":"m4328","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223356_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.37711","article-title":"Head-To-Head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIB, multinational, prospective, randomized study","volume":"65","author":"Weinblatt","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223356_bib42","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-To-Head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223356_bib43","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib44","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/annrheumdis-2011-200882","article-title":"Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients","volume":"71","author":"Du Pan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib45","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/art.41754","article-title":"Nonserious infections in patients with rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis","volume":"73","author":"Bechman","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223356_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","article-title":"Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German rabbit register","volume":"81","author":"Redeker","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib47","doi-asserted-by":"crossref","first-page":"20-33","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-Based rheumatoid arthritis registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-223356_bib49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223356_bib50","author":"Food and Drug Administration of the United States"},{"key":"10.1136\/ard-2022-223356_bib51","author":"European Medicines Agency"},{"key":"10.1136\/ard-2022-223356_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled oral surveillance trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib53","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised concerto trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib54","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose Weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223356_bib55","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/acr2.11188","article-title":"Subcutaneous Sarilumab in patients with rheumatoid arthritis who previously received subcutaneous Sarilumab or intravenous tocilizumab: an open-label extension of a randomized clinical trial","volume":"2","author":"Emery","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-223356_bib56","doi-asserted-by":"crossref","first-page":"rkac002","DOI":"10.1093\/rap\/rkac002","article-title":"Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to Janus kinase inhibitors or tocilizumab in regular care in Germany","volume":"6","author":"Tony","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"10.1136\/ard-2022-223356_bib57","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223356_bib58","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/kes150","article-title":"Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the realistic phase IIIB study","volume":"51","author":"Weinblatt","year":"2012","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223356_bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib60","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2020-217528","article-title":"Two-Year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the tara trial","volume":"79","author":"van Mulligen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24\u2005months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib62","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3899\/jrheum.121427","article-title":"Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis","volume":"40","author":"Aguilar-Lozano","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223356_bib63","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (preserve): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223356_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac285","article-title":"Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy","author":"Amstad","year":"2022","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223356_bib65","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-Tnf antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223356_bib66","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.semarthrit.2020.08.007","article-title":"Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies","volume":"50","author":"Xie","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223356_bib67","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/BOR.0b013e3282f7c706","article-title":"Malignancy and biologic therapy in rheumatoid arthritis","volume":"20","author":"Askling","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard-2022-223356_bib68","article-title":"Risk of cancer recurrence or new tumors in RA patients with prior malignancies treated with various biologic agents","author":"Strangfeld","year":"2013","journal-title":"Arhritis Rheum"},{"key":"10.1136\/ard-2022-223356_bib69","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from oral surveillance","author":"Charles-Schoeman","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223356_bib71","author":"Eli Lilly and Company"},{"key":"10.1136\/ard-2022-223356_bib72","author":"Eli Lilly and Company"},{"key":"10.1136\/ard-2022-223356_bib73","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","article-title":"Risk profiling for a refractory course of rheumatoid arthritis","volume":"49","author":"B\u00e9c\u00e8de","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223356_bib74","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/annrheumdis-2022-222583","article-title":"EULAR 75-year anniversary: commentaries on key ARD papers from 1947","volume":"81","author":"Kvien","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib75","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/annrheumdis-2022-222621","article-title":"Greetings from the editor","volume":"81","author":"Smolen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223356_bib76","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1136\/ard-2022-223356corr1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000}}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724086199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724086199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:25:50Z","timestamp":1749806750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724086199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0003496724086199"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223356","relation":{"erratum":[{"id-type":"doi","id":"10.1136\/ard-2022-223356corr1","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}